Value
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.8 |
| P/S | 7.4 |
| EV/EBITDA | 4.3 |
| Fwd P/E | 7.4 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 16.9x
- ▸PEG: 0.11
SHC · Why this verdict
Why Sotera Health (SHC) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Ethylene oxide sterilization capacity relies on a single supplier — a high-severity concentration risk — meaning any supply disruption, regulatory action against that supplier, or pricing negotiation failure could halt the company's core operations. Bear case | The company discloses a second ethylene oxide supply agreement within 12 months, reducing concentration risk below single-source dependency. | →Stable |
| CounterEO supply relationships in industrial sterilization are typically long-established with high switching costs on both sides; the existing supplier has equally strong incentives to maintain the relationship. | ||
Free cash flow conversion at 123% of net income and a Piotroski F-Score of 8 out of 9 demonstrate that the business consistently generates more cash than its accounting earnings suggest, reflecting high-quality recurring revenue from healthcare sterilization contracts. Quality breakdown | Free cash flow conversion remains above 100% of net income over the next 12 months as long-term customer contracts continue to generate predictable cash. | →Stable |
| CounterThe Piotroski score partially reflects low capital expenditure relative to depreciation; if the company needs to reinvest significantly in its sterilization facilities, FCF conversion could normalize downward. | ||
The company beat earnings estimates in 3 of its last 4 quarters with an average positive surprise of 11.4%, with beats of 19.1%, 7.1%, and 15.9% in the three most recent quarters, demonstrating consistent operational outperformance. Catalyst breakdown | Earnings beats continue in at least 2 of the next 3 quarters, maintaining the track record of outperformance. | →Stable |
| CounterThe most recent quarter was only an inline result rather than a beat; if this signals a deceleration in outperformance, the beat streak may be peaking. | ||
Debt-to-equity of 3.6 imposes a maximum leverage penalty on quality ratings and implies that a meaningful portion of equity returns are being generated through financial leverage rather than operational strength — a risk that could accelerate in a higher-rate environment. Risk breakdown | Debt-to-equity falls below 2.5 over the next 12 months through free cash flow deployment toward debt reduction. | →Stable |
| CounterThe analyst price target implies 24% upside and the company generates 123% FCF relative to net income, suggesting the free cash flow capacity to meaningfully reduce debt; the high leverage may be intentional and manageable. | ||
Ethylene oxide sterilization capacity relies on a single supplier — a high-severity concentration risk — meaning any supply disruption, regulatory action against that supplier, or pricing negotiation failure could halt the company's core operations.
→StableBear case
- Expectation
- The company discloses a second ethylene oxide supply agreement within 12 months, reducing concentration risk below single-source dependency.
CounterEO supply relationships in industrial sterilization are typically long-established with high switching costs on both sides; the existing supplier has equally strong incentives to maintain the relationship.
Free cash flow conversion at 123% of net income and a Piotroski F-Score of 8 out of 9 demonstrate that the business consistently generates more cash than its accounting earnings suggest, reflecting high-quality recurring revenue from healthcare sterilization contracts.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 100% of net income over the next 12 months as long-term customer contracts continue to generate predictable cash.
CounterThe Piotroski score partially reflects low capital expenditure relative to depreciation; if the company needs to reinvest significantly in its sterilization facilities, FCF conversion could normalize downward.
The company beat earnings estimates in 3 of its last 4 quarters with an average positive surprise of 11.4%, with beats of 19.1%, 7.1%, and 15.9% in the three most recent quarters, demonstrating consistent operational outperformance.
→StableCatalyst breakdown
- Expectation
- Earnings beats continue in at least 2 of the next 3 quarters, maintaining the track record of outperformance.
CounterThe most recent quarter was only an inline result rather than a beat; if this signals a deceleration in outperformance, the beat streak may be peaking.
Debt-to-equity of 3.6 imposes a maximum leverage penalty on quality ratings and implies that a meaningful portion of equity returns are being generated through financial leverage rather than operational strength — a risk that could accelerate in a higher-rate environment.
→StableRisk breakdown
- Expectation
- Debt-to-equity falls below 2.5 over the next 12 months through free cash flow deployment toward debt reduction.
CounterThe analyst price target implies 24% upside and the company generates 123% FCF relative to net income, suggesting the free cash flow capacity to meaningfully reduce debt; the high leverage may be intentional and manageable.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Sotera Health is a high-quality healthcare sterilization business with 123% free cash flow conversion, a Piotroski F-Score of 8/9, and three consecutive earnings beats, but single-supplier dependency on one ethylene oxide source and high leverage at 3.6x debt-to-equity constrain near-term entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 7.6 |
| ROA | 5.7 |
| Gross margin | 7.1 |
| Op margin | 10.0 |
| Net margin | 5.0 |
| Current ratio | 9.5 |
| FCF quality | 9.1 |
| Moat | 6.9 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 123% FCF/NI
- ▸Strong Piotroski F-Score: 8/9
- ▸High-quality business
Growth
7.5/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.0 |
| EPS growth | 10.0 |
Momentum
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.3 |
- ▸Overbought (RSI 71)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.9 |
| Price target | 6.8 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Heavy insider selling — $772,676,197 (15.112% of mkt cap)
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.3 |
| quality rank | 7.5 |
| growth rank | 5.0 |
- ▸Superior ROE vs peers
Technical
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.5 |
| support resistance | 0.7 |
| 52w position | 8.1 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.4 |
| days to cover | 4.1 |
| volatility | 5.6 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 4.1 |
| debt equity | 1.4 |
- ▸High IV: 87%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 8.2 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Downgraded from BUY WAIT — price $17.93 has reached target $17.75. No upside to wait for.
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|SANITY:WAIT+price>=TPPassed (5)
- MOMENTUM:7.5>=5.5
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-0.1=NEGATIVE
- INSIDER:15.11%=EXTREME
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.13
Upside
-1.9%
Downside
14.2%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 1.77>1.3
Investment implication
The C-path quality+growth combination triggered the HOLD_IF_HOLDING verdict: quality 7.8 and growth 7.5 both clear their thresholds, with asymmetric R:R of -0.13 supporting the read.
The strongest dimensions are Quality at 7.8, Growth at 7.5, and Momentum at 7.5; the weakest are Insider at 3.0, Technical at 3.1, and Peer rank at 4.2. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -0.13 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Cash Conversion Business
Trip ifFree cash flow conversion falls below 80% of net income for 2 consecutive quarters, indicating the high-quality cash generation thesis is deteriorating.
- P2Eo Single Supplier Concentration
Trip ifCompany discloses a supply disruption from the single EO supplier lasting more than 30 days, affecting more than 20% of sterilization capacity.
- P3Strong Earnings Beat Streak
Trip ifEarnings surprise falls below 0% in at least 2 of the next 4 quarters, reversing the consistent beat pattern.
- P4High Leverage Pullback Entry Setup
Trip ifDebt-to-equity ratio rises above 4.0, more than 11% above current levels, indicating leverage is increasing rather than being reduced through cash generation.